Mualliflar

  • Сулейманова Д.Н., Таджиева З., Шамсутдинова М.И.

##semicolon##

гемостаз, гиперкоагуляция, тяжелое отторжение COVID–19, гемостаз, фибриноген, антитромбин, D–димер, протромбиновый индекс.

##submission.citations##

Галстян Г.М. Коагулопатия при COVID–19. Пульмонология. 2020; 30 (5): 645–657. DOI: 10.18093/0869–0189–2020–30– 5–645–65

Шатохин Ю.В., Снежко И.В., Рябикина Е.В. Нарушение гемостаза при коронавирусной инфекции. Южно–Российский журнал терапевтической практики. 2021; 2(2): 6–15. https:// doi.org/10.21886/2712–8156–2021–2–2–6–15

Воинов В.А., Илькович М.М., Ковалев М.Г., Карчевский К.С., Исаулов О.В. Эктракорпоральная детоксикация и иммунокоррекция в лечении новой коронавирусной пневмонии. Клиника пульмонологии Санкт–Петербургского ГМУ им. И.П.Павлова. 2021.

Casini A., Alberio L., Angelillo–Scherrer A. et al. Thromboprophylaxis and laboratory monitoring for in–hospital patients with COVID–19 – a Swiss consensus statement by the Working Party Hemostasis. Swiss Med. Wkly. 2020; 150: w20247. DOI: 10.4414/smw.2020.20247

Giuseppe Lippi 1, Mario Plebani 2, Brandon Michael Henry Mar. Thrombocytopenia associated with severe coronavirus disease 2019 (COVID–19) infections: a meta–analysis3Wedge Kim Acta... 2020 Jul; 506: 145–148. doi: 10.1016 / j.cca.2020.03 .022. Epub 2020).

Hunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID–19. March 25, 2020.

Ivascu N.S., Fitzgerald M., Ghadimi K., Patel P., Evans A.S., Goeddel L.A. et al. Heparin–induced thrombocytopenia: a review for cardiac anesthesiologists and intensivists. J Cardiothorac Vasc Anesth. 2019; 33 (2): 511–520. doi: 10.1053/j.jvca.2018. 10.035.

Prince M., Wenham T. Heparin–induced thrombocytopenia. Postgrad Med J. 2018; 94:453 –457. doi: 10.1136/ postgradmedj–2018–135702.

Salter B.S., Weiner M.M., Trinh M.A., Heller J.,Evans A.S., Adams D.H., Fischer G.W. Heparin–induced thrombocytopenia: A comprehensive clinical review. J Am Coll Cardio. 2016; 67:2519–32. doi.org/ 10.1016/j. jacc.2016.02.073.

Sarah Balagholi, RasulDabbaghi, PeymanEshghi, sevedAsadollahMousavi, FarhadHeshmati, SaeedMohammadi. Potential of therapeutic plasmapheresis in treatment of COVID–19 patients: Immunopathogenesis and coagulopathy. TransfusApher Sci. 2020 Dec; 59(6): 102993. Published online 2020 Nov 2. doi: 10.1016/j.transci.2020.102 993

Selleng K., Warkentin T. E., Greinacher A. Heparin–induced thrombocytopenia in intensive care patients. Crit. Care Med. 2007;35 (4):1165–76. doi: 10.1097/01. CCM.0000259538.02375. A5.

Semigolovskii N.Yu., Vavilova T.V., Kashchenko V.A., Semigolovskii S.N., Sapegin A.A. Heparin–induced thrombocytopenia in patients with venous throm–boembolic complications. Meditsinskii sovet. 2018; 5:110–16.] (In Russ.).

Soy M., Keser G., Atagündüz P., Tabak F., Atagündüz I., Kayhan S. Cytokine storm in COVID–19: pathogenesis and overview of anti–inflammatory agents used intreatment. ClinRheumatol. 2020: 1. May30. [Google Scholar]

Thachil J et al. ISTH interim guidance on recognition and management of coagulopathy in COVID–19. published: 25 March 25, 2020

Watson H., Davidson S., Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin–induced thrombocytopenia: second edition. Br J Haematol. 2019; 159:528–40. doi: 10.1111/bjh.12059.

Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. J Thromb Haemost. 2013 doi: 10.1111/jth.12155.

Xiaobo Yang, Qingyu Yang, Yaxin Wang, Yongran Wu, Jiqian Xu, Yuan Yu, You Shang Thrombocytopenia and its association with mortality in patients with COVID–19 J Thromb Haemost. 2020 Jun;18(6):1469–1472. doi: 10.1111/jth.14848. Epub 2020 May 4.